SurModics, Inc. (SRDX)
Stock Price Chart
Key Info
| Market Cap | 558.36M |
| Revenue (ttm) | 103.14M |
| Net Income (ttm) | 7.62M |
| Shares Out | 13.65M |
| EPS (ttm) | 0.56 |
| PE Ratio | 73.07 |
| Forward PE | 666.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $40.92 |
| Previous Close | $40.86 |
| Change ($) | 0.06 |
| Change (%) | 0.15% |
| Day's Open | 41.23 |
| Day's Range | 40.39 - 41.20 |
| Day's Volume | 13,752 |
| 52-Week Range | 22.06 - 49.00 |
More Stats
| Market Cap | 558.36M |
| Enterprise Value | 497.80M |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 13.65M |
| Float | 13.14M |
| EPS (basic) | 0.57 |
| EPS (diluted) | 0.56 |
| FCF / Share | 1.52 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.37% |
| FCF Yield | 3.71% |
| Payout Ratio | n/a |
| Shares Short | 364,740 |
| Short Ratio | 7.41 |
| Short % of Float | 2.78% |
| Beta | 0.98 |
| PE Ratio | 73.07 |
| Forward PE | 666.67 |
| P/FCF Ratio | 26.94 |
| PS Ratio | 5.41 |
| PB Ratio | 4.28 |
| Revenue | 103.14M |
| Operating Income | 4.62M |
| Net Income | 7.62M |
| Free Cash Flow | 20.73M |
| Net Cash | 60.56M |
| Net Cash / Share | 4.44 |
| Gross Margin | 32.78% |
| Operating Margin | 4.48% |
| Profit Margin | 7.40% |
| FCF Margin | 20.10% |
| ROA | 2.31% |
| ROE | 6.12% |
| ROIC | 6.00% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100 | 81.34 | 73.11 | 71.37 | 61.90 | 57.44 | 56.13 | 51.93 | 52.76 | 54.49 |
| Revenue Growth | 23.04% | 11.25% | 2.45% | 15.3% | 7.76% | 2.33% | 8.1% | -1.57% | -3.18% | - |
| Gross Profit | 86.44 | 67.34 | 61.69 | 60.46 | 53.28 | 49.42 | 48.23 | 44.51 | 46.01 | 47.68 |
| Operating Income | 6.47 | -8.80 | 7.10 | 16.86 | 19.09 | 18.58 | 18.82 | 16.34 | 15.52 | 11.99 |
| Net Income | 7.59 | -4.46 | 3.93 | 9.99 | 11.95 | 12.03 | 15.17 | 10.23 | -18.51 | -21.09 |
| Shares Outstanding | 13.39 | 13.16 | 13.15 | 13.00 | 13.03 | 13.63 | 14.46 | 17.32 | 17.42 | 17.37 |
| Earnings Per Share | 0.55 | -0.34 | 0.29 | 0.76 | 0.90 | 0.87 | 1.03 | 0.59 | -1.06 | -1.21 |
| EPS Growth | - | - | -61.84% | -15.56% | 3.45% | -15.53% | 74.58% | - | - | - |
| Operating Cash Flow | 8.04 | 34.05 | 14.05 | 25.17 | 15.02 | 18.18 | 17.67 | 16.11 | 19.96 | 22.01 |
| Capital Expenditures | -5.99 | -9.09 | -6.43 | -8.10 | -1.84 | -2.28 | -1.84 | -0.76 | -1.55 | -2.78 |
| Free Cash Flow | 2.05 | 24.96 | 7.62 | 17.06 | 13.19 | 15.91 | 15.82 | 15.35 | 18.40 | 19.23 |
| Cash & Equivalents | 55.29 | 65.02 | 48.34 | 46.94 | 55.59 | 46.55 | 25.71 | 29.66 | 38.44 | 20.50 |
| Net Cash / Debt | 55.29 | 65.02 | 48.34 | 46.94 | 55.59 | 46.55 | 25.71 | 29.66 | 38.44 | 20.50 |
| Assets | 160 | 164 | 137 | 133 | 98.71 | 105 | 102 | 104 | 157 | 170 |
| Liabilities | 37.35 | 55.53 | 25.04 | 26.06 | 6.84 | 6.14 | 8.11 | 9.33 | 17.17 | 15.92 |
| Book Value | 123 | 109 | 112 | 107 | 91.87 | 98.75 | 93.82 | 94.99 | 140 | 154 |
Company Profile
Company Details
| Full Name | SurModics, Inc. |
| Country | United States |
| Employees | 369 |
| CEO | Gary R. Maharaj |
Stock Information
| Ticker Symbol | SRDX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Unique Identifier | NASDAQ: SRDX |
| IPO Date | March 4, 1998 |
Description
Surmodics, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.